Exane Derivatives’s Haemonetics HAE Stock Holding History

Exane Derivatives’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,000	Closed	-$87.2K	–	848
2020 Q3	$87.2K	Buy	+1,000	New	+$87.4K	0.03%	318

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Exane Derivatives's HAE Position: Q4 2020 in Review

Exane Derivatives sold out of Haemonetics (HAE) in Q4 2020, closing a stake of 1,000 shares — an estimated $87.2K sold.

Exane Derivatives first reported a position in HAE in Q3 2020 and held it in 1 quarter. The position peaked at $87.2K in Q3 2020. 286 funds tracked by Wall St. Rank hold HAE as of Q4 2020.

Exane Derivatives reported no remaining Haemonetics position as of Q4 2020 after selling out during the quarter.
Exane Derivatives sold 1,000 Haemonetics shares in Q4 2020, an estimated $87.2K.
Exane Derivatives first reported a position in Haemonetics in Q3 2020 and held it in 1 quarter.
Exane Derivatives's Haemonetics position peaked at $87.2K in Q3 2020.
286 funds tracked by Wall St. Rank held Haemonetics as of Q4 2020.

Based on Exane Derivatives's 13F filing for Q4 2020, filed 27 Jan 2021.